Derek Buhl
Scientific Director AbbVie
Derek Buhl is a Scientific Director in Neuroscience Precision Medicine at AbbVie. He is a neurophysiologist and systems neuroscientist whose work has spanned from running early target discovery projects to implementing end-to-end biomarker strategies for clinical studies in CNS disorders, primarily in schizophrenia, mood disorders, and sleep disorders. His work focuses on the development of translational, circuit-based biomarkers and validation of novel digital tools for remote clinical monitoring to optimize patient stratification, dose rationale, and efficacy measures of pharmacological intervention.
Seminars
Tuesday 15th September 2026
Precision Psychiatry 2.0: Reimagining Frameworks, Tools & Clinical Pathways to Deliver Individualized Mental Health Care
9:20 am
- Positioning EEG as a scalable, translational biomarker, integrating neural signals with clinical and biological data to improve patient stratification and development decision-making
- Moving beyond symptom-based diagnoses by leveraging EEG-derived neurophysiological signatures to reduce heterogeneity and define biologically coherent subgroups
- Translating EEG, digital phenotyping, and AI-enabled analytics from research tools into deployable assets across clinical trials, endpoints, and real-world settings
- Aligning pharmacological and non-pharmacological interventions with EEG-informed neural biomarkers to guide target engagement, dose selection, and personalized treatment strategies
Tuesday 15th September 2026
Precision Psychiatry 2.0: Reimagining Frameworks, Tools & Clinical Pathways to Deliver Individualized Mental Health Care
9:00 am
- Positioning EEG as a scalable, translational biomarker, integrating neural signals with clinical and biological data to improve patient stratification and development decision making
- Moving beyond symptom based diagnoses by leveraging EEG derived neurophysiological signatures to reduce heterogeneity and define biologically coh erent subgroups
- Translating EEG, digital phenotyping, and AI enabled analytics from research tools into deployable assets across clinical trials, endpoints, and real world settings
- Aligning pharmacological and non pharmacological interventions with EEG informed neural biomarkers to guide target engagement, dose selection, and personalized treatment strategies
Tuesday 15th September 2026
Panel Discussion: Evaluating Unmet Needs in Sleep: Navigating EEG Utility & Limitations Across Complex Sleep Architecture
3:15 pm
- Defining which facets of sleep (onset, maintenance, early awakening, quality, or EEG specific signals) truly matter as clinical biomarkers
- Understanding the practical and scientific limits of EEG in psychiatric sleep research: specificity, invasiveness, and placebo susceptibility
- How sponsors (orexin programs, sleep promoting or circadian targeting drugs) and EEG tech vendors interpret sleep architecture in different disease contexts
- Identifying core unmet needs in insomnia and sleep dysregulation across mood and psychiatric disorders, and what measurement innovation is required
Tuesday 15th September 2026
Panel Discussion: Evaluating Unmet Needs in Sleep: Navigating EEG Utility & Limitations Across Complex Sleep Architecture
3:15 pm
- Defining which facets of sleep (onset, maintenance, early awakening, quality, or EEG specific signals) truly matter as clinical biomarkers
- Understanding the practical and scientific limits of EEG in psychiatric sleep research: specificity, invasiveness, and placebo susceptibility
- How sponsors (orexin programs, sleep promoting or circadian targeting drugs) and EEG tech vendors interpret sleep architecture in different disease contexts
- Identifying core unmet needs in insomnia and sleep dysregulation across mood and psychiatric disorders, and what measurement innovation is required
Tuesday 15th September 2026
Chair’s Opening Remarks & Welcome
9:00 am
Tuesday 15th September 2026
Chair’s Opening Remarks
8:55 am
Tuesday 15th September 2026
Chair’s Closing Remarks & End of Focus Day
4:00 pm
Tuesday 15th September 2026
Chair’s Closing Remarks & End of Focus Day
4:00 pm
